B

BioNote Inc
KRX:377740

Watchlist Manager
BioNote Inc
KRX:377740
Watchlist
Price: 4 580 KRW Market Closed
Market Cap: 467.4B KRW
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+27%
Revenue
Forecast
N/A
Operating Income
Forecast
N/A
Net Income
Forecast
N/A

Wall Street
Price Targets

Price Targets Summary
BioNote Inc

Wall Street analysts forecast BioNote Inc stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BioNote Inc is 5 814 KRW with a low forecast of 5 757 KRW and a high forecast of 5 985 KRW.

Lowest Forecast
Wall Street Target
5 757 KRW
26% Upside
Average Forecast
Wall Street Target
5 814 KRW
27% Upside
Highest Forecast
Wall Street Target
5 985 KRW
31% Upside
Lowest
Price Target
5 757 KRW
26% Upside
Average
Price Target
5 814 KRW
27% Upside
Highest
Price Target
5 985 KRW
31% Upside
BioNote Inc Competitors:
Price Targets
PRAX
Praxis Precision Medicines Inc
133% Upside
CDMO
Avid Bioservices Inc
2% Upside
688520
Sinocelltech Group Ltd
47% Upside
PAR
Paradigm Biopharmaceuticals Ltd
172% Upside
PRAX
Praxis Precision Medicines Inc
133% Upside
CDMO
Avid Bioservices Inc
2% Upside
688520
Sinocelltech Group Ltd
47% Upside
PAR
Paradigm Biopharmaceuticals Ltd
172% Upside
302440
SK Bioscience Co Ltd
19% Upside
6855
Ascentage Pharma Group International
6% Upside
X
688278
Xiamen Amoytop Biotech Co Ltd
34% Upside
DNLI
Denali Therapeutics Inc
146% Upside

Revenue
Forecast

Revenue Estimate
BioNote Inc

For the last 4 years the compound annual growth rate for BioNote Inc's revenue is -36%. The projected CAGR for the next 2 years is 38%.

-36%
Past Growth
38%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
BioNote Inc

For the last 4 years the compound annual growth rate for BioNote Inc's operating income is -62%. The projected CAGR for the next 2 years is 39%.

-62%
Past Growth
39%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
BioNote Inc

For the last 4 years the compound annual growth rate for BioNote Inc's net income is -43%. The projected CAGR for the next 2 years is -24%.

-43%
Past Growth
-24%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BioNote Inc's stock price target?
Price Target
5 814 KRW

According to Wall Street analysts, the average 1-year price target for BioNote Inc is 5 814 KRW with a low forecast of 5 757 KRW and a high forecast of 5 985 KRW.

What is BioNote Inc's Revenue forecast?
Projected CAGR
38%

For the last 4 years the compound annual growth rate for BioNote Inc's revenue is -36%. The projected CAGR for the next 2 years is 38%.

What is BioNote Inc's Operating Income forecast?
Projected CAGR
39%

For the last 4 years the compound annual growth rate for BioNote Inc's operating income is -62%. The projected CAGR for the next 2 years is 39%.

What is BioNote Inc's Net Income forecast?
Projected CAGR
-24%

For the last 4 years the compound annual growth rate for BioNote Inc's net income is -43%. The projected CAGR for the next 2 years is -24%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 249,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.